Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
NCT ID: NCT01553448
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
75 participants
OBSERVATIONAL
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies gene expression in samples from younger patients with neuroblastoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma
NCT01520233
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Biomarkers in Young Patients With Neuroblastoma
NCT01169376
Biomarkers in Samples From Young Patients With Neuroblastoma
NCT01358604
Study of Specimens From Young Patients With Neuroblastoma
NCT00958659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine whether TβRIII expression and TGF-β signaling decrease in advanced-stage neuroblastoma (NBL) and whether these changes are confined to the Schwannian stroma.
* Determine whether sTβRIII levels and TGF-β signaling correlate with NBL stage, tumor stroma content, surface TβRIII expression, and TGF-β signaling.
OUTLINE: Archived paraffin-embedded tissue and plasma samples are analyzed for TβRIII expression, TGF-β signaling, and SMAD3 expression and phosphorylation by immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and other assays. Surface expression of TβRIII in the neuroblastic and stromal tumor components are correlated with matched circulating levels of soluble TβRIII. Results are then correlated with each patient's outcome data, including stage.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
protein expression analysis
enzyme-linked immunosorbent assay
immunohistochemistry staining method
laboratory biomarker analysis
medical chart review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tissue samples and matched plasma samples available from 1 of the following groups:
* Patients with low-stage (International Neuroblastoma Staging System \[INSS\] stage 1 or 2) neuroblastoma (NBL)
* Patients with advanced-stage (INSS stage 3 or 4) NBL
* Patients with stage 4S NBL
* Clinical and/or outcome data associated with the tissue and plasma samples including INSS stage, age, MYCN amplification status, chromosomal alterations, and 5-year survival, if known
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gerard C. Blobe, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Duke University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ANBL12B6
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000728527
Identifier Type: OTHER
Identifier Source: secondary_id
ANBL12B6
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00706
Identifier Type: REGISTRY
Identifier Source: secondary_id
ANBL12B6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.